in 2011 [28] showed NIS promoter was methylated in (7/13) of DTCs (without specifying PTC or FTC separately), (1/3) of hyperthyroid, and (1/5) of normal cases and suggested that aberrant methylation of NIS may be an early change in thyroid tumorigenesis regardless of cell type. This evidence concerns the gene SLC5A5 and thyroid gland disorder.